Health Care & Life Sciences » Biotechnology | Circassia Pharmaceuticals PLC

Circassia Pharmaceuticals PLC | Balance Sheet

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
30,615.00
186,590.00
203,800.00
117,400.00
59,500.00
40,700
Total Accounts Receivable
4,712.00
9,524.00
16,200.00
16,400.00
25,400.00
9,100
Inventories
-
-
3,000.00
4,600.00
5,000.00
4,200
Other Current Assets
498.00
1,949.00
700.00
-
-
-
Total Current Assets
35,825.00
198,063.00
223,700.00
138,400.00
89,900.00
54,000
Net Property, Plant & Equipment
-
309.00
1,300.00
1,400.00
1,400.00
500
Total Investments and Advances
195.00
103.00
200.00
900.00
500.00
100
Intangible Assets
2,012.00
2,050.00
246,800.00
176,800.00
209,700.00
230,700
Other Assets
-
-
-
-
85,200.00
3,000
Total Assets
38,032.00
200,525.00
489,200.00
334,100.00
402,400.00
307,400
ST Debt & Current Portion LT Debt
2,012.00
-
-
-
-
Accounts Payable
3,461.00
2,746.00
5,100.00
9,200.00
22,700.00
Other Current Liabilities
2,514.00
7,020.00
43,200.00
12,300.00
8,100.00
Total Current Liabilities
7,987.00
9,766.00
48,300.00
21,500.00
30,800.00
Deferred Taxes
-
-
14,000.00
15,300.00
8,400.00
Other Liabilities
-
-
-
-
122,700.00
Total Liabilities
7,987.00
9,766.00
79,500.00
53,400.00
177,600.00
Common Equity (Total)
29,993.00
190,759.00
408,500.00
280,700.00
224,800.00
Total Shareholders' Equity
30,045.00
190,759.00
408,500.00
280,700.00
224,800.00
Total Equity
30,045.00
190,759.00
409,700.00
280,700.00
224,800.00
Liabilities & Shareholders' Equity
38,032.00
200,525.00
489,200.00
334,100.00
402,400.00
Accumulated Minority Interest
-
-
1,200.00
-
-
Preferred Stock (Carrying Value)
52.00
-
-
-
-

About Circassia Pharmaceuticals

View Profile
Address
Northbrook House
Oxford Oxfordshire OX4 4GA
United Kingdom
Employees -
Website http://circassia.com
Updated 07/08/2019
Circassia Pharmaceuticals Plc is a biopharmaceutical company, which engages in the development and commercialization of allergy, asthma, and respiratory products. It operates through the following segments: NIOX, Respiratory, and US AZ Collaboration. The NIOX segment provides a portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide.